**Study:** ARX-945-RA-II

**Protocol:** CT-204-II  
**Sponsor:** Ardentis Biotherapeutics Ltd.  
**Site No.:** 104  **Subject ID:** 1

Document: Disease Activity / Efficacy Assessment (Repeating)

| **Visit** | **Tender** | **Swollen** | **CRP (mg/L)** | **DAS28 (CRP)** | **HAQ-DI** | **Pt VAS** | **Phy VAS** | **ACR20** | **ACR50** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | 18 | 14 | 12.6 | 5.9 | 1.5 | 65 | 60 | N | N |
| Week 2 | 15 | 12 | 11.3 | 5.5 | 1.4 | 60 | 58 | N | N |
| Week 4 | 11 | 9 | 9.4 | 4.9 | 1.2 | 55 | 50 | Y | N |
| Week 8 | 7 | 6 | 7.1 | 4.2 | 1.0 | 45 | 42 | Y | Y |
| Week 10 | 6 | 5 | 6.8 | 4.0 | 0.9 | 40 | 38 | Y | Y |